Diabetes Mellitus Is an Independent Risk Factor for a Stiff Left Atrial Physiology After Catheter Ablation for Atrial Fibrillation

Moon-Hyun Kim, Hee Tae Yu*, Yoon Jung Park, Tae-Hoon Kim, Boyoung Joung, Moon-Hyoung Lee and Hui-Nam Pak†

Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, Seoul, South Korea

Background: Scar tissue formation after catheter ablation for atrial fibrillation (AF) may adversely affect the diastolic properties of the left atrium (LA), which can result in a stiff LA physiology in a small proportion of patients. In this study, we aimed to explore the relationship between diabetes mellitus and a stiff LA physiology after AF catheter ablation (AFCA).

Methods: A total of 1,326 patients who underwent de novo AFCA, and baseline and 1-year follow-up echocardiographies were enrolled. After 1:3 propensity score (PS) matching for age, sex, and AF type, we compared 211 patients with DM with 633 patients without DM. A stiff LA physiology was defined as estimated pulmonary arterial pressure increase of >10 mmHg and a right ventricular systolic pressure of >35 mmHg at 1-year follow-up echocardiography. Pulmonary vascular resistance (PVR) was estimated using echocardiographic parameters.

Results: Among the 844 PS-matched patients, a stiff LA physiology was observed in 32 patients (4.1%). The patients with DM showed a higher peak LA pressure ($p < 0.001$) and greater LA wall stress ($p = 0.001$) than did those without. A stiff LA physiology was independently associated with DM [Odds ratio (OR) = 2.39, 95% confidence interval (CI) 1.02–5.59, $p = 0.045$], empirical extra-pulmonary vein LA ablation (OR = 3.14, 95% CI 1.07–9.3, $p = 0.038$) and the ΔPVR (OR = 1.78, 95% CI 1.37–2.31, $p < 0.001$). The ΔPVR was independently associated with DM ($\beta = 0.37$, 95% CI 0.06–0.67, $p = 0.020$) and a stiff LA physiology ($\beta = 1.40$, 95% CI 0.70–2.10, $p < 0.001$). During the 38.8 ± 29.3months follow-up, the incidence of the clinical recurrence of AF was significantly higher in the patients with a stiff LA physiology than in those without (log rank $p = 0.032$).

Conclusion: A stiff LA physiology was independently associated with DM because of the relatively small decrease in the PVR after AFCA in this population. The patients with a stiff LA physiology had worse rhythm outcomes after AFCA than those without.

Keywords: diabetes mellitus, atrial fibrillation, catheter ablation, pulmonary vascular resistance, stiff left atrium
INTRODUCTION

Atrial fibrillation (AF) is a prevalent arrhythmia that increases morbidity and socioeconomic burden worldwide (1). Currently, AF catheter ablation (AFCA) is an effective rhythm control method for patients with AF (1). Various clinical benefits of AFCA have been reported, including reduced mortality in patients with heart failure (2), reduced risk of stroke and improvements in cognitive function (3).

However, AFCA is a destructive procedure that uses heating or freezing as an energy source (4) and inevitably leads to atrial tissue damage, resulting in necrosis, and scarring. Previous studies have reported that AFCA, particularly extra-pulmonary vein (PV) left atrium (LA) ablation, increases LA stiffness, and worsens post-ablation diastolic function. Repeated catheter ablation has also been reported to increase LA pressure and stiffness compared with the de novo procedure (5). Patients with a higher LA pressure or stiffness or greater wall stress had a higher recurrence rate after AFCA (6). Stiff LA syndrome was first reported as symptomatic pulmonary arterial hypertension caused by a decreased LA function after mitral valve surgery (7). Recently, it has been reported that stiff LA syndrome may develop after extensive AFCA (8). In previous studies, diabetes mellitus (DM) was reported as independent risk factors for stiff LA syndrome (9). To date, there is limited knowledge on the mechanism of stiff LA syndrome after AFCA, and the relationship between stiff LA syndrome and metabolic causes, such as DM, is unknown.

In this study, we applied the term “stiff LA physiology” and used previously reported echocardiographic parameters to define this condition (10). One-year follow-up parameters were used to investigate the incidence and clinical features of a stiff LA physiology in patients who underwent AFCA. The purpose of this study was to explore the association between DM and a stiff LA physiology. We also attempted to elucidate the mechanism of a stiff LA physiology using pulmonary vascular resistance (PVR) derived from echocardiographic findings (11).

MATERIALS AND METHODS

Study Population

The study protocol adhered to the principles of the Declaration of Helsinki and was approved by the institutional review board of the Yonsei University Health System. All patients provided written informed consent for inclusion in the Yonsei AF Ablation Cohort Database. Among 3,777 patients who underwent de novo AFCA in the Yonsei AF Ablation Cohort from September 2009 to October 2020, 1,326 patients who underwent voltage substrate mapping, baseline echocardiography, and 1-year follow-up echocardiography were enrolled in the study. DM was defined as HbA1c ≥ 6.5% or taking DM medication before the procedure (12). The study patients were divided into two groups according to the presence of DM via propensity score (PS) matching. After 1:3 PS matching for age, sex, and AF type, we compared 211 patients with DM with 633 patients without DM (Figure 1). The exclusion criteria of this study were as follows: (1) permanent AF refractory to electrical cardioversion; (2) AF with rheumatic valvular disease; (3) previous cardiac surgery with concomitant AF surgery or AFCA; (4) unmeasurable voltage map during sinus rhythm owing to frequent re-initiation of AF; and (5) no transthoracic echocardiography at baseline or 1 year later.

Electrophysiological Mapping and Radiofrequency Catheter Ablation

Three-dimensional (3D) electroanatomical mapping (NavX; St. Jude Medical, Inc., Minnetonka, MN) using a circumferential PV mapping catheter (Lasso; Biosense-Webster Inc., Diamond Bar, CA) through a long sheath (Schwartz left; St. Jude Medical, Inc.) was performed. Pulmonary venography was performed after trans-septal punctures using a pigtail catheter. The 3D geometry of both the LA and PV was merged using the NavX system and then generated with 3D spiral computed tomographic (CT) images. Systemic anticoagulation with intravenous heparin was achieved to maintain an activated clotting time of 350-400s during the procedure. An open-irrigated tip catheter (Celsius; Johnson & Johnson Inc., Diamond Bar, CA; NaviStar ThermoCool, Biosense Webster Inc.; ThermoCool SF, Biosense Webster Inc.; ThermoCool SmartTouch, Biosense Webster Inc.; CoolFlex, St. Jude Medical, Inc.; 30–35 W; 47°C; FlexAbility, St. Jude Medical, Inc.; and Tacti-Cath, St. Jude Medical, Inc.) was used for AFCA. All patients underwent a de novo procedure involving circumferential PV isolation (CPVI). Most patients (94.8%) received a cavitricuspid isthmus (CTI) block during the procedure unless there was an atrioventricular conduction disease. We conducted an additional linear ablation including a roof line, a posterior inferior line, and an anterior line, especially in the patients with persistent AF. Left lateral isthmus ablation, right atrial ablation, and complex fractionated electrogram ablation were performed in a minority of the patients at the operator's discretion. We defined extra-PV
LA ablation as an additional linear ablation with or without complex fractionated electrogram ablation following CPVI. The procedure ended when there was no immediate recurrence of AF within 10 min after cardioversion with isoproterenol infusion (5–10 mcg/min).

**Echocardiographic and Cardiac Computed Tomographic Evaluations**

All patients underwent transthoracic echocardiography at baseline and at the 1-year follow-up. The LA diameter, left ventricular (LV) ejection fraction (LVEF), LV mass index (LVMI), peak trans mitral flow velocity (E), and peak septal mitral annular velocity (Em) on tissue Doppler echocardiography were measured in accordance with the American Society of Echocardiography guidelines (13). Retrograde systolic tricuspid flow was obtained from the apical four-chamber view to measure the peak tricuspid pressure drop using continuous-wave Doppler. The LV outflow tract (LVOT) diameter and velocity-time integral (VTI) were measured from the parasternal long axis view and apical three-chamber view using pulsed-wave Doppler. PVR was estimated using the following equation: PVR = pulmonary arterial mean pressure (PAMP) echo–pulmonary capillary wedge pressure (PCWP)/cardiac output (CO) echo (11). PAMP echo was calculated as follows: Pulmonary arterial systolic pressure (PASP) echo = 0.61 + 2 mmHg. PCWP echo was calculated as follows: 1.24 × E/Em + 1.9 mmHg (14). Stroke volume (SV) and CO echo were estimated at the LVOT as follows: SV = (LVOT diameter/2)^2 × LVOT VTI and CO echo = SV × heart rate, respectively (15). These parameters were defined as the PVR-related parameters. The delta value was calculated as follows: delta (Δ) = value at the 1-year follow-up echocardiography–value at the baseline echocardiography.

Three-dimensional spiral CT (64 Channel, Light Speed Volume CT, Philips, Brilliance 63; Amsterdam, the Netherlands) was performed to define the PV anatomy. The 3D spiral CT images of the LA were analyzed using an image processing workstation (Aquarius; TeraRecon, Inc., Foster City, CA).

**LA Pressure, LA Wall Thickness, and LAW Stress Measurement**

Intracardiac electrograms and hemodynamic measurements were recorded using the Prucka Cardio Lab electrophysiology system (General Electric Medical Systems, Inc., Milwaukee, WI). For catheter access to the LA, a trans-septal puncture approach was used. During AFCA, the LA pressure was measured during sinus rhythm after the trans-septal puncture using a 6-F pigtail catheter (A&A Medical Device, Inc., Gyeonggi-do, Republic of Korea) that was inserted into the LA through a long sheath (Schwartz left 1; St. Jude Medical, Inc.). When the initial rhythm was AF, we measured the LA pressure during sinus rhythm after terminating the AF via internal cardioversion (2–10 J biphasic shocks, Lifepak12; Physiocontrol, Ltd., Redmond, WA), followed by a 3-min waiting period to allow for recovery from atrial stunning from cardioversion (5, 16). We analyzed the peak LA pressure (LAPpeak; v wave), LA nadir pressure (LAPnadir; x wave), and LA mean pressure (LAPmean). These parameters have been defined and calculated in our previous study (17).

We developed a customized software (AMBER, Laonmed Inc., Seoul, Republic of Korea) that measured the LAW thickness by applying Laplace’s equation to the cardiac CT images. The LAW thickness was calculated as a numerical streamline connecting the endocardium and epicardium using the Euler method after solving the vector field with Laplace’s equation, the partial differential equation in the 3D space (18). Thereafter, the mean LAW thickness was used as a parameter to calculate the LAW-stress. LAW-stress (dyn/cm^2) was calculated using the law of Laplace [s = (P × r)/2 h (s, wall stress; P, pressure; r, radius; h, wall thickness)] (19). The peak LA pressure during sinus rhythm was directly measured during AF, and the LA radius was defined as half of the LA anteroposterior (AP) diameter on transthoracic echocardiography. Therefore, LAW-stress was calculated using the following equation: LAW-stress = (peak LA pressure × LA AP diameter)/(4 × LAW thickness). It was expressed in dyn/cm^2 (1 mmHg = 1,333 dyn/cm^2).

**Post-ablation Management and Follow-Up**

The patients were instructed to visit the outpatient clinic at 1, 3, 6, and 12 months and then every 6 months thereafter or whenever symptoms occurred after RFCA. Electrocardiography was performed at every visit. Twenty-four-hour Holter monitoring was performed at 3, 6, and 12 months and every 6 months thereafter according to the 2012 Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society Expert consensus statement guidelines (20). The patients who experienced symptoms of palpitations underwent Holter/event-monitor examinations to investigate the possibility of arrhythmia recurrence. AF recurrence was defined as any episode of atrial tachycardia (AT) or AF lasting for more than 30s. All electrocardiographic documentations of AF recurrence after a 3-month blanking period were classified as clinical recurrence.

**Statistical Analysis**

Continuous variables were expressed as means ± standard deviations and compared using Student’s t-test. Categorical variables were reported as counts (percentages) and compared using the chi-square or Fisher’s exact test. Logistic regression analysis was used to investigate the variables related to a stiff LA physiology and DM. Linear regression analysis was used to investigate the variables related to the ΔPVR. The variables with p-values of <0.05 in the univariate analysis were selected for the multivariate analysis. Kaplan–Meier analysis with the log-rank test was used to analyze the probability of freedom from AF/AT recurrence after AFCA. Statistical significance was set at p-values of <0.05. The Statistical Package for the Social Sciences version 25.0 for Windows (IBM Corp., Armonk, NY) and R software version 3.6.2 (The R Foundation for Statistical Computing, Vienna, Austria) were used for the data analysis.
### RESULTS

#### Clinical Characteristics of the Patients With DM and a Stiff LA Physiology

1,326 patients were included for analysis and 211 patients were diagnosed with DM (15.9%). The baseline characteristics according to the presence of DM before and after PS matching are shown in Table 1. A total of 844 patients (male: 69.0%) PS-matched for age, sex, and AF type had an average age of 64.0 ± 8.7 years, and 58.6% had paroxysmal AF. The patients with DM had more comorbidities, such as hypertension ($p < 0.001$) and vascular disease ($p < 0.001$) than those without DM. The patients with DM also had a higher LA pressure and greater peak E/Em ($p < 0.001$) and LVMI ($p = 0.001$) than did those without. Like the echocardiographic findings, there was no significant difference in the echocardiographic parameters at baseline. At 1-year follow-up echocardiography, the patients with a stiff LA physiology after AFCA showed a larger LA diameter ($p < 0.001$) and higher E/Em ($p = 0.001$) and LVMI ($p = 0.001$) than did those without. Like the echocardiographic findings, there was no significant difference in the PVR-related parameters at baseline. There was no significant difference in the LA diameter, E/A ratio, or 3D volumetric analysis between the two groups (Table 1). Among the 844 patients, a stiff LA physiology was observed in 32 patients (4.1%). The prevalence of DM was higher in the patients with a stiff LA physiology than in those without ($p = 0.037$). The peak LA pressure ($p = 0.010$) and LAW stress ($p = 0.024$) were also higher in the patients with a stiff LA physiology than in those without (Supplementary Table 1).

#### Echocardiographic Characteristics in the Patients With a Stiff LA Physiology and DM

The echocardiographic characteristics according to the presence of a stiff LA physiology are shown in Table 2. There was no significant different in the parameters at baseline. At 1-year follow-up echocardiography, the patients with a stiff LA physiology after AFCA showed a larger LA diameter ($p < 0.001$) and higher E/Em ($p = 0.001$) and LVMI ($p = 0.001$) than did those without. Like the echocardiographic findings, there was no significant difference in the PVR-related parameters at baseline. However, at 1-year follow-up, the PAMP ($p < 0.001$) and PCWP ($p = 0.001$) were higher in the patients with a stiff LA physiology than in those without. Moreover, the patients with a stiff LA physiology showed a higher $\Delta$PVR ($p < 0.001$) than did those without (Figure 2A).

The echocardiographic characteristics according to the presence of DM are presented in Supplementary Tables 3, 4. While there was no significant difference in the LA diameter, the LVEF, right ventricular systolic pressure (RVSP), and E/Em ($p < 0.001$) were significantly higher in the patients with DM than in those without a baseline. The $\Delta$PVR was also significantly

---

**Table 1** Baseline characteristics according to the presence of DM.

| Before propensity scoring (N = 1,326) | After propensity scoring (N = 844) |
|---------------------------------------|----------------------------------|
| **DM (N = 211)** | **Non-DM (N = 1,115)** | **P-value** | **DM (N = 211)** | **Non-DM (N = 633)** | **P-value** |
| Age, years | 64.2 ± 8.8 | 58.8 ± 10.8 | <0.001 | 64.2 ± 8.8 | 64.1 ± 8.7 | 0.911 |
| Paroxysmal AF, % | 121 (57.3) | 722 (64.6) | 0.051 | 121 (57.3) | 374 (59.1) | 0.687 |
| Male, % | 147 (69.7) | 762 (68.2) | 0.687 | 147 (69.7) | 435 (68.7) | 0.864 |
| Body mass index, kg/m² | 25.4 ± 3.0 | 24.8 ± 3.0 | <0.001 | 25.4 ± 3.0 | 24.8 ± 2.8 | <0.001 |
| CHA²DS²VASc score | 3.5 ± 1.6 | 1.6 ± 1.4 | 0.003 | 3.5 ± 1.8 | 2.0 ± 1.5 | 0.013 |
| Congestive heart failure, % | 28 (13.3) | 169 (15.1) | 0.528 | 28 (13.3) | 96 (15.2) | 0.575 |
| Hypertension, % | 161 (76.3) | 471 (42.1) | <0.001 | 161 (76.3) | 320 (50.6) | <0.001 |
| Stroke, % | 39 (18.5) | 141 (12.6) | 0.028 | 39 (18.5) | 90 (14.2) | 0.151 |
| Vascular disease, % | 56 (26.5) | 114 (10.2) | <0.001 | 56 (26.5) | 89 (14.1) | <0.001 |

| **Comparisons of Cardiac Dimensions** | **Comparisons of Clinical Characteristics** |
|----------------------------------------|------------------------------------------|
| LA pressure, peak, mmHg | 24.9 ± 10.5 | 22.1 ± 9.6 | <0.001 | 24.9 ± 10.5 | 21.9 ± 9.5 | <0.001 |
| LA voltage | 1.4 ± 0.7 | 1.3 ± 0.7 | 0.023 | 1.4 ± 0.7 | 1.4 ± 0.7 | 0.797 |
| LA wall thickness | 1.9 ± 0.4 | 2.0 ± 0.3 | 0.466 | 1.9 ± 0.4 | 2.0 ± 0.3 | 0.074 |
| LA wall stress | 193.6 ± 111.5 | 164.1 ± 95.2 | 0.001 | 193.6 ± 111.5 | 162.0 ± 94.3 | 0.001 |

Data are presented as mean ± SD for continuous variables and as proportions for categorical variables. DM, diabetes mellitus; AF, atrial fibrillation; LA, left atrium; BSA, body surface area; CTI, cavo-tricuspid isthmus; PV, pulmonary vein.
TABLE 2 | Echocardiographic characteristics according to the presence of a stiff LA physiology.

| Echocardiographic findings | Baseline | 1-year follow up | Delta value |
|---------------------------|----------|-----------------|-------------|
| Stiff LA physiology (N = 32) | No stiff LA physiology (N = 812) | p-value | Stiff LA physiology (N = 32) | No stiff LA physiology (N = 812) | p-value | Stiff LA physiology (N = 32) | No stiff LA physiology (N = 812) | p-value |
| LA diameter, mm | 43.5 ± 5.5 | 42.3 ± 6.0 | 0.263 | 42.7 ± 5.1 | 39.1 ± 5.7 | 0.001 | −0.8 ± 4.5 | −3.2 ± 4.7 | 0.005 |
| LVEF, % | 63.1 ± 7.6 | 62.7 ± 8.6 | 0.837 | 66.0 ± 10.7 | 64.8 ± 7.5 | 0.368 | 3.0 ± 7.1 | 2.0 ± 7.8 | 0.510 |
| E/Em | 12.2 ± 4.6 | 10.9 ± 4.4 | 0.085 | 17.7 ± 10.1 | 11.2 ± 4.7 | 0.001 | 5.3 ± 7.4 | 0.3 ± 3.9 | 0.001 |
| RVSP, mmHg | 27.8 ± 7.2 | 27.2 ± 6.9 | 0.639 | 44.8 ± 8.4 | 26.0 ± 6.0 | <0.001 | 17.0 ± 4.3 | −0.3 ± 17.6 | <0.001 |
| LVMI, g/m² | 98.7 ± 18.2 | 96.5 ± 23.3 | 0.619 | 109.0 ± 23.8 | 96.1 ± 21.6 | 0.001 | 8.0 ± 21.9 | −0.3 ± 17.6 | 0.013 |

Data are presented as mean ± SD for continuous variables. LA, left atrium; LVEF, left ventricular ejection fraction; E/Em, the ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); RVSP, right ventricular systolic pressure; LVMI, left ventricular mass index; PVR, pulmonary vascular resistance; PAMP, pulmonary artery mean pressure; PCWP, pulmonary capillary wedge pressure.

higher in the patients with DM than in those without (p = 0.012) (Figure 2B).

**Association of a Stiff LA Physiology With DM and the ΔPVR**

We investigated the association between a stiff LA physiology and DM using multivariate logistic regression analysis and linear regression analysis. In the adjusted model, a stiff LA physiology was independently associated with DM [OR = 2.39 (1.02–5.59), p = 0.045], the pericardial fat volume [OR = 1.01 (1.00–1.02), p = 0.004], empirical extra-PV LA ablation [OR = 3.14 (1.07–9.3), p = 0.038], and the ΔPVR [OR = 1.78 (1.37–2.31), p < 0.001]. We analyzed two multivariate models separately because the 1-year follow-up PVR and ΔPVR had multicollinearity. A stiff LA physiology was also associated with the 1-year follow-up PVR [OR = 1.69 (1.25–2.28), p = 0.001] (Table 3). To evaluate the contribution of diabetes to stiff LA physiology, an additional multivariate logistic analysis excluding patients of extra PV LA
**TABLE 3 | Logistic regression analysis of the stiff LA physiology in the patients.**

|                      | Univariate analysis |                       | Multivariate analysis |                       | Multivariate analysis |                       |
|----------------------|---------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                      | OR (95% CI)         | P-value               | OR (95% CI)           | P-value               | OR (95% CI)           | P-value               |
| Age                  | 1.042 (0.999–1.088) | 0.058                 | 1.088 (0.378–3.134)   | 0.876                 | 0.881 (0.302–2.575)   | 0.817                 |
| Male                 | 0.854 (0.406–1.798) | 0.678                 |                       |                       |                       |                       |
| Paroxysmal AF        | 0.355 (0.169–0.746) | 0.006                 | 2.935 (1.278–6.742)   | 0.011                 | 2.386 (1.019–5.878)   | 0.045                 |
| Body mass index      | 1.052 (0.935–1.183) | 0.397                 |                       |                       |                       |                       |
| Diabetes mellitus    | 2.122 (1.029–4.374) | 0.042                 | 2.935 (1.278–6.742)   | 0.011                 | 2.386 (1.019–5.878)   | 0.045                 |
| Hypertension         | 0.969 (0.475–1.975) | 0.931                 |                       |                       |                       |                       |
| Congestive heart failure | 2.000 (0.877–4.559) | 0.099                 |                       |                       |                       |                       |
| Stroke               | 0.563 (0.169–1.877) | 0.350                 |                       |                       |                       |                       |
| Vascular disease     | 1.945 (0.881–4.296) | 0.100                 |                       |                       |                       |                       |
| LA diameter          | 1.034 (0.975–1.095) | 0.263                 |                       |                       |                       |                       |
| LVEF                 | 1.004 (0.963–1.047) | 0.837                 |                       |                       |                       |                       |
| E/Em                 | 1.059 (0.992–1.130) | 0.087                 |                       |                       |                       |                       |
| LA volume/BSA        | 1.013 (0.999–1.026) | 0.060                 |                       |                       |                       |                       |
| Pericardial fat volume | 1.008 (1.002–1.014) | 0.007                 | 1.010 (1.003–1.017)   | 0.006                 | 1.011 (1.003–1.018)   | 0.004                 |
| LA pressure, peak*   | 1.061 (1.027–1.097) | <0.001                |                       |                       |                       |                       |
| LA voltage*          | 0.389 (0.205–0.738) | 0.004                 |                       |                       |                       |                       |
| LA wall stress*      | 1.004 (1.001–1.007) | 0.005                 | 1.002 (0.999–1.006)   | 0.153                 | 1.003 (0.999–1.006)   | 0.144                 |
| Extra PV LA ablation | 2.731 (1.316–5.664) | 0.007                 | 3.494 (1.190–10.259)  | 0.023                 | 3.144 (1.067–9.262)   | 0.038                 |
| Extra PV trigger     | 0.318 (0.043–2.377) | 0.264                 |                       |                       |                       |                       |
| Baseline PVR         | 0.939 (0.757–1.164) | 0.564                 |                       |                       |                       |                       |
| 1-year follow up PVR | 1.396 (1.117–1.742) | 0.003                 | 1.689 (1.251–2.281)   | 0.001                 |                       |                       |
| Delta PVR            | 1.141 (1.176–1.767) | <0.001                | 1.782 (1.372–2.314)   | <0.001                |                       |                       |

*LA wall stress was included in the multivariate analysis due to multicollinearity among three variables. Two multivariate models were separately presented because 1-year follow up PVR and delta PVR had a multicollinearity to each other. LA, left atrium; AF, atrial fibrillation; LVEF, left ventricular ejection fraction; E/Em, the ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); BSA, body surface area; PV, pulmonary vein; PVR, pulmonary vascular resistance.

Ablation group was performed. As a result, in this subgroup, stiff LA physiology also showed an independent association with 1-year follow-up PVR or ΔPVR (Supplementary Table 5). The multivariate logistic regression analysis revealed that the ΔPVR was independently associated with DM [β = 0.37 (0.06–0.67), p = 0.020], the peak LA pressure [β = −0.02 (-0.03–0.00), p = 0.034], and a stiff LA physiology [β = 1.40 (0.70–2.10), p < 0.001] in the adjusted model (Table 4). The multivariate logistic regression analysis revealed that DM was independently associated with hypertension [OR = 2.25 (1.47–3.43), p < 0.001], vascular disease [OR = 1.78 (1.10–2.90), p = 0.020], and the ΔPVR [OR = 1.03 (1.01–1.05), p = 0.001] in the adjusted model (Supplementary Table 6).

**Clinical Recurrence of AF After RFCA and a Stiff LA Physiology**

During the 38.8 ± 29.3 month follow-up, the incidence of the clinical recurrence of AF was significantly higher in the patients with a stiff LA physiology than in those without (log rank p = 0.032) (Figure 3A, Supplementary Table 7). There was no difference in this incidence between the patients with and without DM (log rank p = 0.364) (Figure 3B).

**DISCUSSION**

Our study investigated the association between a stiff LA physiology after AFCA and DM using echocardiographic estimated PVR. We found that a stiff LA physiology was independently associated with DM, the ΔPVR, and empirical extra-PV LA ablation after adjustment for age, sex, and AF type. Compared with the patients without DM, a relatively small decrease in the PVR was observed in the patients with DM after AFCA, which may explain the mechanistic association between DM and a stiff LA physiology. Although the incidence of a stiff LA physiology was low, the clinical recurrence of AF after AFCA was associated with the presence of a stiff LA physiology in our study population.

**Stiff LA Physiology After AFCA**

Stiff LA syndrome was first described in a patient who developed pulmonary artery hypertension with dyspnea after mitral valve replacement (7). Recently, the concept of stiff LA syndrome has recently been applied to patients who have undergone AFCA. The main clinical findings are dyspnea, congestive heart failure, pulmonary hypertension, and large v waves recorded on PCWP or LA pressure tracings in the absence of marked mitral regurgitation (21). Operators tend to create more ablation...
TABLE 4 | Linear regression analysis of the ΔPVR in the patients.

|                     | Univariate analysis     |          | Multivariate analysis     |          |
|---------------------|-------------------------|----------|---------------------------|----------|
|                     | B (95% CI)   | P-value  | B (95% CI)       | P-value  |
| Age                 | −0.010 (−0.025–0.004) | 0.158    | 0.365 (0.057–0.673)    | 0.020    |
| Male                | 0.061 (−0.211–0.333)  | 0.660    |                           |          |
| Paroxysmal AF       | −0.047 (−0.302–0.207) | 0.715    |                           |          |
| Body mass index     | 0.023 (−0.020–0.067)  | 0.294    |                           |          |
| Diabetes mellitus   | 0.383 (0.096–0.671)   | 0.009    |                           |          |
| Hypertension        | 0.069 (−0.18–0.323)   | 0.594    |                           |          |
| Congestive heart failure | −0.162 (−0.533–0.210) | 0.394    |                           |          |
| Stroke              | 0.014 (−0.341–0.369)  | 0.937    |                           |          |
| Vascular disease    | −0.036 (−0.366–0.293) | 0.829    |                           |          |
| LA diameter         | −0.017 (−0.038–0.004) | 0.122    |                           |          |
| LVEF                | 0.008 (−0.007–0.023)  | 0.287    |                           |          |
| LA volume/BSA       | −0.006 (−0.011–0.000) | 0.034    | −0.006 (−0.011–0.000)   | 0.057    |
| Pericardial fat volume | 0.000 (−0.002–0.003) | 0.742    |                           |          |
| LA pressure, peak   | −0.016 (−0.030–0.000) | 0.018    | −0.015 (−0.029–0.001)   | 0.034    |
| LA voltage          | 0.049 (−0.195–0.237)  | 0.609    |                           |          |
| LA wall stress      | −0.001 (−0.003–0.000) | 0.097    |                           |          |
| Stiff LA physiology | 1.065 (0.427–1.702)   | 0.001    | 1.402 (0.701–2.103)     | <0.001   |
| Extra PV LA ablation| 0.076 (−0.183–0.335)  | 0.564    |                           |          |
| Extra PV trigger    | −0.060 (−0.488–0.367) | 0.781    |                           |          |

PVR, pulmonary vascular resistance; AF, atrial fibrillation; LA, left atrium; LVEF, left ventricular ejection fraction; BSA, body surface area; PV, pulmonary vein.

lesions to reduce the AF recurrence, but extensive ablation lesions usually result in more scar formation in the LA. Moreover, recent clinical trials have revealed no additional benefit of linear ablation or electrogram-guided ablation compared with a CPVI alone (22). In our recent study, extra-PV LA ablation markedly increased the LA pressure and worsened the diastolic function more than CPVI alone; however, there was no difference in the symptoms (5). In addition, we recently conducted a study on a stiff LA physiology defined using the RVSP. Similar to previous findings, DM, a low mean LA voltage, and extra-PV LA ablation were identified as risk factors (4).

**Association Between a Stiff LA Physiology and DM**

In this study, patients who developed a stiff LA physiology showed an increased PVR after AFCA. There were no differences in the echocardiographic findings or PVR-related parameters at baseline. Among the patients with a stiff LA physiology, the SV increased, while the heart rate decreased after the procedure. There was no difference found in the CO between the two groups. Conversely, the PAMP and PCWP significantly increased in the patients with a stiff LA physiology. In particular, the increase in the PAMP was greater than that in the PCWP.
which resulted in an increase in the PVR. Generally, the LA chamber is characterized by high compliance. It serves an atrial mechanical function through atrial contraction and as a reservoir by maintaining a low LA pressure during atrial relaxation and filling periods (23). Atrial contraction represents a wave in the LA pressure. Subsequent atrial relaxation shows a drop in the x wave, indicating early atrial filling in the PV, followed by an increase in the LA pressure and simultaneous LV contraction. As ventricular contraction continues, the RV also contracts, and the SV enters the LA through the pulmonary circulation and creates a v wave with passive filling (24). In a stiff LA physiology, LV compliance is reduced by atrial scarring and late systole is pronounced, which increases the v wave and PCWP. This can lead to pulmonary vascular remodeling, RV dysfunction, and increased pulmonary artery pressure. Previous studies have reported elevations in the E/Em reflecting diastolic dysfunction in patients with a stiff LA physiology (5). LV diastolic dysfunction increases the pulmonary artery pressure and RVSP and is attributed to a stiff LA physiology.

We found that a stiff LA physiology was independently associated with DM and the ΔPVR, and found an association between DM and the ΔPVR. In the comparison between the patients with and without DM, both groups showed a decrease in PVR after the procedure; however, the decrease in the PVR was smaller in the patients with DM. Regardless of DM, all patients showed a decrease in PVR after AFCA. Among the factors involved in estimated PVR, CO increased, PAMP decreased, and PCWP increased after AFCA. CO is affected by SV and HR, and as previously reported that HR increases in decreased, and PCWP increased after AFCA. CO is affected by SV and HR, and as previously reported that HR increases in sinus rhythm after AFCA (25). Some studies showed that CO increases after AFCA (26). In addition, we previously reported an observation of increased LA pressure after AFCA (5). For the reasons described above, in the current analysis, it appears that the estimated PVR decreased after the procedure. However, the baseline PVR was significantly lower in the patients with DM, which resulted in a smaller ΔPVR. The reason why the baseline PVR was smaller in the patients with DM is that diastolic dysfunction occurs frequently among them, which increases the E/Em and PCWP (27). DM can lead to LA remodeling due to LA subendocardial fibrosis, oxidative stress, inflammation, and increased renin-angiotensin-aldosterone system activity as well as LV diastolic dysfunction (28). LA remodeling can increase the PCWP and decrease the PVR. Another study found that DM and hyperglycemia decreased pulmonary artery compliance and increased the RV afterload and RV remodeling in patients with pulmonary artery hypertension (29).

**Study Limitations**

This study had several limitations. First, this was a single-center, observational, retrospective cohort study. Herein, we included highly selective patients who underwent de novo AFCA at a tertiary hospital. The change in the PVI technique was not clearly reflected as it had a long recruitment period of 11 years. Second, the definition of stiff LA syndrome included the patient’s symptoms; however, we could not obtain data on the symptoms and thereby used the concept of a stiff LA “physiology” rather than “syndrome.” We defined a stiff LA physiology using the RVSP on echocardiography. In previous studies, LA stiffness was evaluated using the peak LA pressure, large v wave pressure, and LA pulse pressure (5, 9, 10). Since there is no gold standard method, LA stiffness was defined using several methods, and the relevant results of each study may be different. Thus, generalization of the results should be considered carefully. Third, the PVR was estimated using the echocardiographic findings. Patients without adequate pre- and post-procedural echocardiographic data were excluded. Potential confounding factors, such as age, comorbidities, medication, heart rate, and rhythm, may also play a role in post-procedural echocardiography. Fourth, we measured the LA pressure during sinus rhythm after cardioversion in the patients with early AF rhythm status. We waited for at least 3 min for the LA pressure to stabilize; however, it was difficult to rule out an effect on the LA after shock. Fifth, since we identified DM before the procedure, data regarding mean blood glucose levels, DM control, and period after diagnosis of DM were not available in this study. Further studies on DM control status including medication use, mean glucose level and stiff LA physiology will be needed. Despite the above limitations, we sought to evaluate the association of DM and a stiff LA physiology after AFCA in the current analysis, and by raising awareness of stiff LA physiology especially in diabetic populations, clinicians can have more attention to treatment options and prognosis for these patients.

**CONCLUSION**

A stiff LA physiology was independently associated with DM because of the relatively small decrease in the PVR after AFCA in this population. The patients with a stiff LA physiology had worse rhythm outcomes after AFCA than in those without.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Institutional Review Board of the Yonsei University Health System. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

M-HK contributed to the conception and design of the work, interpretation of data, and drafting of the manuscript. HY and H-NP contributed to the conception and design of the work and critical revision of the manuscript. YP, T-HK, BJ, and M-HL contributed to the conception and design of the work and
FUNDING

This work was supported by grants [H121C0011] from the Ministry of Health and Welfare and a grant [NRF-2020R1A2B5B01001695] from the Basic Science Research Program run by the National Research Foundation of Korea, which is funded by the Ministry of Science, ICT & Future Planning. This study was also supported by a Severance Hospital Research fund for Clinical excellence (SHRC) (C-2021-0019) and a new faculty research seed money grant of Yonsei University College of Medicine for 2021 (2021-32-0043).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.828478/full#supplementary-material

REFERENCES

1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. (2021) 42:373–498. doi: 10.1093/eurheartj/ehaa612

2. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. (2018) 378:417–27. doi: 10.1056/NEJMoa1707855

3. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. (2011) 22:839–45. doi: 10.1111/j.1540-8167.2011.02035.x

4. Lee JH, Kwon OS, Yu HT, Kim TH, Uhm JS, Joung B, et al. Risk factors for stiff left atrial physiology 1 year after catheter ablation of atrial fibrillation. Front Physiol. (2021) 12:740600. doi: 10.3389/fphys.2021.740600

5. Park JW, Yu HT, Kim TH, Uhm JS, Joung B, Lee MH, et al. Atrial fibrillation catheter ablation increases the left atrial pressure. Circ Arrhythm Electrophysiol. (2019) 12:e007073. doi: 10.1161/CIRCEP.118.007073

6. Linhart M, Lewalter T, Mittmann-Braun EL, Karbach NC, Andrie RP, Hammerstingl C, et al. Left atrial pressure as predictor for recurrence of atrial fibrillation after pulmonary vein isolation. J Interv Card Electrophysiol. (2013) 38:107–14. doi: 10.1080/10401310-9-9803-9

7. Pilote L, Marpole D, Sniderman A. Stiff left atrial syndrome. Can J Cardiol. (1988) 4:255–7.

8. Packer M. Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation. Eur Heart J. (2019) 40:1873–9. doi: 10.1093/eurheartj/ezh284

9. Gibson DN, Di Biase L, Mohanty P, Patel JD, Bai R, Sanchez J, et al. Stiff left atrial syndrome after catheter ablation for atrial fibrillation: clinical characterization, prevalence, and predictors. Heart Rhythm. (2011) 8:1364–71. doi: 10.1016/j.hrthm.2011.02.026

10. Witt CM, Fenstad ER, Cha YM, Kane GC, Kushwaha SS, Hodge DO, et al. Increase in pulmonary arterial pressure after atrial fibrillation catheter ablation increases the left atrial pressure. Circ Arrhythm Electrophysiol. (2012) 12:e007073. doi: 10.1161/CIRCEP.118.007073

11. Lindqvist P, Soderberg S, Gonzalez MC, Tossavainen E, Henein MY. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous doppler echocardiography and cardiac catheterization study. J Eur J Echocardiogr. (2011) 12:961–6. doi: 10.1093/ejechoc/eed062

12. American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. (2019) 42:S13–8. doi: 10.2337/dc19-5002

13. Mitchell C, Rahko PS, Blauwt LA, Canaday B, Finsuen JA, Foster MC, et al. Guidelines for Performing a comprehensive transesophageal echocardiographic examination in adults: recommendations from the American society of echocardiography. J Am Soc Echocardiogr. (2019) 32:1–64. doi: 10.1016/j.echo.2018.06.004

14. Naghue SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. (1997) 30:527–33. doi: 10.1016/S0735-1097(97)00344-6

15. Blanco P, Rationale for using the velocity-time integral and the minute distance for assessing the stroke volume and cardiac output in point-of-care settings. Ultrasound J. (2020) 12:21. doi: 10.1186/s13089-020-01070-x

16. Park J, Joung B, Uhm JS, Young Shim C, Hwang C, Hyoung Lee M, et al. High left atrial pressures are associated with advanced electroanatomical remodeling of left atrium and independent predictors for clinical recurrence of atrial fibrillation after catheter ablation. Heart Rhythm. (2014) 11:953–60. doi: 10.1016/j.hrthm.2013.04.009

17. Park J, Yang PS, Kim TH, Uhm JS, Kim JY, Joung B, et al. Low left atrial pressure contributes to the clinical recurrence of atrial fibrillation after catheter ablation in patients with structurally and functionally normal heart. PLoS ONE. (2015) 10:e0143853. doi: 10.1371/journal.pone.0143853

18. Kwon O-S, Lee J, Lim S, Park J-W, Han H-J, Yang S-H, et al. Accuracy and clinical feasibility of 3D-myoocardial thickness map measured by cardiac computed tomography. Int J Arithryth. (2020) 21:12. doi: 10.1186/s42444-020-00020-w

19. Wang W, Buehler D, Martinland AM, Feng XD, Wang YJ. Left atrial wall tension directly affects the restoration of sinus rhythm after Maze procedure. Eur J Cardiothorac Surg. (2011) 40:77–82. doi: 10.1016/j.ejcts.2011.04.014

20. Fang L, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. (2012) 14:528–606. doi: 10.1093/europace/euo027

21. Yang Y, Liu Q, Wu Z, Li X, Xiao Y, Tu T, et al. Stiff heart syndrome: a complication undergoing radiofrequency catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. (2016) 27:884–9. doi: 10.1111/jce.12966

22. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. (2012) 14:528–606. doi: 10.1093/europace/euo027

23. Linhart M, Lewalter T, Mittmann-Braun EL, Karbach NC, Andrie RP, Hammerstingl C, et al. Left atrial pressure as predictor for recurrence of atrial fibrillation after pulmonary vein isolation. J Interv Card Electrophysiol. (2013) 38:107–14. doi: 10.1080/10401310-9-9803-9

24. Reddy YNV, El Sabbagh A, Packer D, Nishimura RA. Evaluation of shortness of breath after atrial fibrillation ablation: Is there a stiff left atrium? Heart Rhythm. (2018) 15:930–5. doi: 10.1016/j.hrthm.2018.01.029

25. Yu HT, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, et al. Prognosis of high sinus heart rate after catheter ablation for atrial fibrillation. Europace. (2017) 19:1132–9. doi: 10.1093/europace/euw142

26. Schmidt M, Daccarett M, Brachmann J. Atrial fibrillation ablation in systemic heart failure patients: a promising tool? Europace. (2010) 12:1–2. doi: 10.1093/europace/eup397
27. Kadappu KK, Boyd A, Eshoo S, Haluska B, Yeo AE, Marwick TH, et al. Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction? *Eur Heart J Cardiovasc Imaging.* (2012) 13:1016–23. doi: 10.1093/ehjci/jes084

28. Tadic M, Cuppidi C. The influence of type 2 diabetes on left atrial remodeling. *Clin Cardiol.* (2015) 38:48–55. doi: 10.1002/clc.22334

29. Whitaker ME, Nair V, Sinari S, Dherange PA, Natarajan B, Trutter L, et al. Diabetes Mellitus associates with increased right ventricular afterload and remodeling in pulmonary arterial hypertension. *Am J Med.* (2018) 131:702. doi: 10.1016/j.amjmed.2017.12.046

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kim, Yu, Park, Kim, Joung, Lee and Pak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.